Академический Документы
Профессиональный Документы
Культура Документы
16 mg Plus or Blo-
press
6
5
y
>
6
5
y
B
M
I
<
3
0
B
M
I
3
0
F
e
m
a
l
e
M
a
l
e
S
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
r
e
d
u
c
t
i
o
n
(
m
m
H
g
)
Candesartan cilexetil 16 mg/HCTZ 12.5 mg
* *
30.8
*P-value < 0.05 vs 32 mg candesartan/12.5 mg HCTZ
*P-value < 0.05 vs 32 mg candesartan *P-value < 0.05 vs 32 mg candesartan/12.5 mg HCTZ
29.5 29.1
30.1
29.5
30.1
Candesartan cilexetil 32 mg
*
*
29.0 28.9 29.1
27.8
29.0
28.3
Dyslip/Nondyslip
S
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
r
e
d
u
c
t
i
o
n
(
m
m
H
g
)
Candesartan cilexetil 16 mg/HCTZ 12.5 mg
D
y
s
l
i
p
i
d
e
m
i
a
N
o
n
d
y
s
l
i
p
i
d
e
m
i
c
S
m
o
k
e
r
N
o
n
s
m
o
k
e
r
W
T
h
r
e
s
h
o
l
d
W
C
<
T
h
r
e
s
h
o
l
d
* *
30.3 29.9
31.2
28.7
30.1
29.2
*
*
Candesartan cilexetil 32 mg
29.5
26.8
30.0
27.8
28.7
27.9
Prior CV-event
Y
e
s
N
o
M
A
U
(
+
)
M
A
U
(
)
G
F
R
6
0
m
l
/
m
i
n
G
F
R
<
6
0
m
l
/
m
i
n
Candesartan cilexetil 16 mg/HCTZ 12.5 mg
S
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
r
e
d
u
c
t
i
o
n
(
m
m
H
g
)
P < 0.001
30.6
29.1
33.4
28.7
29.3
30.1
P = 0.035 P = 0.026
Candesartan cilexetil 32 mg
40
35
30
25
20
15
10
5
0
40
35
30
25
20
15
10
5
0
40
35
30
25
20
15
10
5
0
S
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
r
e
d
u
c
t
i
o
n
(
m
m
H
g
)
S
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
r
e
d
u
c
t
i
o
n
(
m
m
H
g
)
S
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
r
e
d
u
c
t
i
o
n
(
m
m
H
g
)
MAU GFR
Smoker/Nonsmoker Waist circumference
BMI < versus 30 Male/female Younger/older
Dyslip/Nondyslip
Prior CV-event MAU GFR
Smoker/Nonsmoker Waist circumference
BMI < versus 30 Male/female
6
5
y
>
6
5
y
B
M
I
<
3
0
B
M
I
3
0
F
e
m
a
l
e
M
a
l
e
D
y
s
l
i
p
i
d
e
m
i
a
N
o
n
d
y
s
l
i
p
i
d
e
m
i
c
S
m
o
k
e
r
N
o
n
s
m
o
k
e
r
W
T
h
r
e
s
h
o
l
d
W
C
<
T
h
r
e
s
h
o
l
d
Y
e
s
N
o
M
A
U
(
+
)
M
A
U
(
)
G
F
R
6
0
m
l
/
m
i
n
G
F
R
<
6
0
m
l
/
m
i
n
Figure 3 Systolic blood pressure reduction patient characteristic (age, gender, and BMI: two panels frst row), concomitant risk factors (hyperlipidemia, waist circumference,
smoking: two panels second row), and end-organ damage (prior CV event, GFR, and MAU: two panels last row).
Notes: *Signifcant differences are indicated (P-value). Other comparisons are not signifcant.
Abbreviations: BMI, body mass index; CV, cardiovascular; GFR, glomerular fltration rate; HCTZ, hydrochlorothiazide; MAU, microalbuminuria.
Vascular Health and Risk Management 2011:7
submit your manuscript | www.dovepress.com
Dovepress
Dovepress
92
Bnner et al
Table 5 Number of patients with adverse events or serious adverse events during the survey and adverse events coded by MedDRA
Version 11.1 (safety population: n = 4600)
Candesartan 16 mg + hydrochlorothiazide
12.5 mg (n = 3337)
Candesartan 32 mg (n = 1263)
n % n %
No adverse events 3313 99.3 1245 98.6
Any adverse events 24 0.7 18 1.4
Serious adverse events 1 0.0 2 0.2
Not serious 23 0.7 16 0.9
MedDRA